Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2019

View Archived Issues

Inducing HER2 expression to sensitize tumors

Size matters for cell prowess

T cells ChAT with blood vessels via neurotransmitter

Debiopharm initiates phase II FUZE study of Debio-1347

Vertex presents positive phase III study data for tezacaftor/ivacaftor

Advaxis initiates phase I/II study of ADXS-503 in patients with NSCLC

Phase III studies of brexpiprazole in patients with bipolar I disorder do not meet primary endpoint

KA-11 demonstrates promising activity in preclinical models of epilepsy and pain

MELK as a novel therapeutic target for neuroblastoma

University of Utah, Stingray Therapeutics patent E-NPP 1 inhibitors/STING modulators

ChemoCentryx synthesizes new PD-1/PD-L1 interaction inhibitors

New PAI-1 inhibitors presented by Eastern Michigan University and the University of Michigan

IL-13Ralpha2 as a novel marker and potential therapeutic target for malignant melanoma

The Helleday Foundation describes ADP-sugar pyrophosphatase inhibitors

New selective estrogen receptor degradation inducers patented by Zeno Royalties & Milestones

Loss of miR-7 facilitates gastric cancer metastasis: a potential biomarker and therapeutic target

TRIM14 promotes tumor invasion in glioblastoma, and may be a novel therapeutic target

AbCellera Biologics and Novartis enter multitarget collaboration

Forbius enters collaboration to evaluate TGF-beta inhibitor in myelofibrosis

Kymab begins phase I/II study of KY-1044 and atezolizumab in advanced cancers

PellePharm initiates phase III study of patidegib topical gel in basal cell nevus syndrome

Transgenic mouse model allows differentiation of platelet and leukocyte functions

ApoE-complement link opens door for new targets in Alzheimer's, atherosclerosis

New 64-week data reported from phase III study of Crysvita in X-linked hypophosphatemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...